### **REMARKS**

#### Claim Amendments

Claims 1, 4-10, and 12-27 are pending. Claim 1 is amended. No new matter is added. Support for the claim amendments may be found in the application as originally filed.<sup>1</sup>

#### Allowable Subject Matter

Applicants greatly appreciate the USPTO's indication that claims 12-27 would be allowable if rewritten in independent form.

# Interview Summary Under 37 C.F.R. § 1.133

On November 19, 2009, Applicants' representatives and Examiner Jeffrey Murray conducted a telephonic interview. Applicants thank Examiner Murray for conducting the interview and courtesies extended by the Examiner during the interview.

During the interview, the parties discussed the indefiniteness rejection. Examiner Murray indicated that this rejection should be overcome by amending claim 1 to recite the heteroaryl groups disclosed on page 5 of the specification (i.e., pyrrole, furyl, thienyl, imidazolyl, thiazolyl, pyrazinyl, indolyl, quinolinyl, isoquinolinyl, tetrazolyl, pyridinyl, pyrazolyl, pyridazinyl, and pyrimidinyl). Examiner Murray also suggested deleting "imidazotriazinone" from claim 1 because the compounds of formula (IA) are necessarily imidazotriazinones (i.e., the recitation of "imidazotriazinone" is unnecessary).<sup>2</sup>

In accordance with the Examiner's suggestions, Applicants have amended claim 1 to recite the heteroaryl groups disclosed on page 5 of the specification, and to delete "imidazotriazinone." Accordingly, Applicants respectfully request an indication that all claims are allowable.

# Claim Rejection under 35 U.S.C. § 112, Second Paragraph

Claims 1 and 4-10 stand rejected under 35 U.S.C. § 112, second paragraph, as allegedly being indefinite.

As discussed above, Examiner Murray suggested claim amendments that should overcome this rejection. Applicants have amended the claims in accordance with the Examiner's suggestions. Accordingly, Applicants respectfully submit that the rejection is moot.

<sup>&</sup>lt;sup>1</sup> See, e.g., Specification, page 5 and Examples.

<sup>&</sup>lt;sup>2</sup> Applicants maintain that this amendment does not affect the claim scope in any way.

### **CONCLUSION**

Applicants respectfully submit that claims are in condition for allowance, and such disposition is earnestly solicited. Should the Examiner believe that any issues remain after consideration of this response, the Examiner is invited to contact the Applicants' undersigned representative to discuss and resolve such issues.

Respectfully submitted,

**HUNTON & WILLIAMS LLP** 

Dated: November 23, 2009

By:

Robert M. Schulman Registration No. 31,196

Alexander H. Spiegler Registration No. 56,625

HUNTON & WILLIAMS LLP Intellectual Property Department 1900 K Street, N.W., Suite 1200 Washington, DC 20006-1109 (202) 955-1500 (general telephone) (202) 955-1899 (direct dial) (202) 778-2201 (facsimile)